Article
Where the case stands
HRSA had planned to start a rebate model on Jan. 1. Under it, participating drugmakers could charge hospitals the full price for certain outpatient drugs and later pay back the difference down to the 340B ceiling price. The American Hospital Association, the Maine Hospital Association and four safety-net systems sued, and on Dec. 29 the U.S. District Court for the District of Maine issued a preliminary injunction. The court found the hospitals likely to succeed on claims that the agency acted arbitrarily by not weighing three decades of reliance on upfront discounts.
On Jan. 7, the First Circuit denied the government’s motion to stay that injunction, finding HHS had not made a strong showing that it was likely to win on the merits. The appeals court described the trial judge’s ruling as careful and thorough. The pilot cannot take effect while the injunction stands, and the underlying appeal will now proceed on the merits.
Why the stakes are high for providers
More than 2,700 hospitals participate in 340B. The AHA has estimated the rebate model would require about two additional full-time staff per hospital on average, and health systems have pegged added operating costs at $150,000 to $500,000 per hospital. The bigger exposure is cash timing. Paying list price and waiting for rebates would shift working capital from hospitals to manufacturers, and the district court accepted that some plaintiff hospitals faced harm as severe as potential closure without relief.
What leaders should do this quarter
- Do not build for the rebate model yet. The injunction means existing purchasing and compliance processes stay in place. Avoid spending on rebate-claims infrastructure until the appeal is decided.
- Keep a contingency plan current. Have pharmacy and finance teams estimate the float that would be tied up if the pilot drugs moved to a pay-then-rebate structure, and identify which service lines carry the most exposure.
- Tighten documentation. Any future model is likely to rely on claims-level data to validate rebates. Clean split-billing records and contract pharmacy data now reduce friction later.
- Brief the board. Trustees should understand that 340B savings fund specific programs, and how a loss of upfront discounts would affect those commitments.
The government can still revise the pilot and build a stronger record, so a redesigned version could return. Finance teams that model the downside now will be able to respond quickly whichever way the First Circuit rules.
Archive entry for Jan 11, 2026, added Nov. 11, 2026.
Sources
- 1st Circuit denies stay, upholds district court’s halt of 340B rebate program (AHA News, Jan 8, 2026)
- 340B rebate model pilot implementation temporarily blocked (Connecticut Hospital Association, Jan 8, 2026)
- Hospitals relieved 340B rebate program is delayed (Chief Healthcare Executive, Jan 5, 2026)
- Federal judge temporarily halts 340B rebate pilot program (340B Health, Dec 29, 2025)